Molcure
MOLCURE is a Japanese AI-driven drug discovery company that combines a proprietary Antibody LLM, physics-based simulations, and an in-house biolab to design antibodies and peptides for enterprise pharmaceutical and biotechnology partners via collaborative research agreements.
- Company typePrivate
- Founded2013
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Molcure does
MOLCURE Inc. is a Tokyo-based (Kawasaki, Kanagawa) AI-driven drug discovery company founded in 2013 that builds proprietary biological foundation models and applies them to antibody and peptide design for pharmaceutical and biotechnology partners. Its core platform integrates a proprietary Antibody LLM built from scratch for biological sequence data, physics-based simulations, and an in-house wet-lab loop (directed evolution, next-generation sequencing, and HAIVE laboratory automation) operating across two Japanese facilities in Kawasaki and the Tsuruoka Science Park. The company has accumulated over 1 billion proprietary antibody and peptide datapoints and reports claimed performance advantages of 10x shorter discovery cycles, 20x more candidates, and up to 100x higher binding strength versus conventional methods.
MOLCURE monetizes through enterprise B2B collaborative research agreements and AI platform licensing, offering four collaboration models: full-cycle screening/NGS/AI analysis, AI-powered de novo discovery, AI-driven lead optimization, and consulting-based problem solving. The company targets large and mid-size pharmaceutical companies as its primary segment, with biotechnology companies as a secondary segment, selling through direct enterprise sales, industry partnering conferences (BioJapan, BIO International Convention, PEGS Boston), and webinars. Disclosed customers include Boehringer Ingelheim, Fujifilm, Teijin Pharma, Ono Pharmaceutical, KM Biologics, Nippon Chemiphar, and Twist Bioscience, totaling 19 partner companies across 28 collaborative projects as of 2026.
The company is privately held and venture-backed, having raised approximately $12 million cumulatively through Series C funding led by JAFCO Group in August 2021, with participation from STRIVE, SBI Investment, Japan Post Capital, GMO VenturePartners, Dai-ichi Life, Nippon Chemiphar, and UTEC. Leadership comprises CEO/CSO Satoshi Tamaki, founder/CIO Ryu Ogawa, Chief AI Officer Batsergelen Myagmar, and Senior Advisor Han Lim (formerly CBO at Atomwise and DeepCure). MOLCURE continues to add strategic partnerships and expand geographically, including its 2026 push into US markets via BIO International Convention participation and a Hitachi co-created confidential AI infrastructure platform.
Molcure firmographics
Firmographics- Name
- Molcure
- Legal name
- MOLCURE Inc.
- Website
- https://molcure.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- MOLCURE is a Japanese AI-driven drug discovery company that combines a proprietary Antibody LLM, physics-based simulations, and an in-house biolab to design antibodies and peptides for enterprise pharmaceutical and biotechnology partners via collaborative research agreements.
- Ownership category
- akta.pro rank
Molcure industry classification
Industry- Product category
- AI-Driven Biologics Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where Molcure is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Molcure business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Collaborative Research Agreements: MOLCURE generates revenue through co-development agreements with pharmaceutical companies where they apply their AI platform to discover and optimize drug candidates for specific targets. These are typically multi-year research partnerships with milestone-based payments.
- AI Platform Licensing: Licensing of proprietary AI technologies and platform capabilities to pharmaceutical and biotech partners for drug discovery applications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Molcure product offering
Product offeringCore offering
MOLCURE provides AI-driven antibody and peptide drug discovery services through a proprietary platform that integrates a biological Large Language Model, physics-based simulations, and high-quality experimental data generated in its in-house automated BioLab. The company engages pharmaceutical and biotechnology partners via multi-year collaborative research agreements covering end-to-end molecular design, AI-powered de novo discovery, lead optimization, and consulting, enabling discovery of high-affinity biotherapeutics against challenging targets.
Product overview
MOLCURE operates as an AI-driven drug discovery company offering a unified platform approach centered on the AI Antibody Discovery Platform. This core platform combines proprietary large language models built from scratch, physics-based simulations, and high-quality experimental data from an in-house biolab containing over 1 billion proprietary molecular datapoints. The platform is accessible through four distinct collaboration models: (1) Screening, NGS, and AI Analysis for end-to-end molecular design support, (2) AI-Powered de novo Discovery for novel molecule identification, (3) AI-Driven Lead Optimization for improving candidate molecules, and (4) Consulting-Based Problem Solving for expert guidance on AI adoption in drug discovery.
Differentiator
Problem solved
Functional benefit
Products and services
- AI Antibody Discovery Platform AI-driven antibody and peptide discovery platform combining proprietary large language models built from scratch for biological data, physics-based simulations, and high-quality experimental data from MOLCURE's in-house BioLab. Used by pharmaceutical and biotechnology partners to discover effective biotherapeutics against challenging targets.
- AI-Powered de novo Antibody/Peptide Discovery Service Collaborative service in which MOLCURE uses its proprietary AI technologies to discover novel antibody and peptide molecules from partner-provided samples, enabling exploration of previously difficult or undruggable targets. Delivered to enterprise pharmaceutical and biotech R&D teams.
- AI-Driven Lead Optimization Service Collaborative service enabling pharmaceutical and biotech partners to optimize their own candidate molecules using MOLCURE's AI-based lead optimization platform, generating molecules with up to 100x higher binding strength than conventional methods.
- AI Drug Discovery Consulting Service Consulting service providing expert guidance to pharmaceutical and biotech partners on leveraging AI technologies to accelerate and enhance their drug discovery processes.
Quantifiable outcome
- Drug candidate discovery cycle reduced to 1/10th of conventional timelines
- +2 more outcomes
Companies that use Molcure
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles2 records
Molcure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Molcure partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor, core and flagship.
- IlluminaminorMOLCURE's CIO Ryu Ogawa spoke at an Illumina-hosted webinar on AI antibody drug discovery, highlighting case studies combining MOLCURE's AI with Illumina's next-generation sequencers.
- HitachicoreMOLCURE and Hitachi announced full-scale co-creation toward launching a confidential AI platform for AI-driven drug discovery. Hitachi is developing the confidential AI infrastructure while MOLCURE provides the drug discovery AI capabilities.
- KM BiologicscoreMOLCURE and KM Biologics entered into a research agreement for AI-powered discovery of next-generation biopharmaceuticals. The partnership aims to create innovative drugs in the blood disease area using MOLCURE's AI drug discovery platform.
- Teijin PharmacoreMOLCURE signed a new agreement with Teijin Pharma to continue joint research using MOLCURE's AI platform for drug discovery.
- FujifilmcoreMOLCURE entered into a joint research agreement with Fujifilm Corporation to advance peptide discovery technology using MOLCURE's AI platform.
- Boehringer IngelheimflagshipMOLCURE entered into a multi-year strategic research agreement with Boehringer Ingelheim to discover and develop innovative antibody drugs for multiple targets using MOLCURE's AI-driven platform technology. This represents one of MOLCURE's most significant pharmaceutical partnerships.
- Ono PharmaceuticalcoreMOLCURE and Ono Pharmaceutical entered into a drug discovery collaboration agreement to discover and develop innovative antibody drugs for multiple targets using MOLCURE's AI-driven platform technology.
- Twist BiosciencecoreTwist Bioscience incorporated MOLCURE's AI technology to augment their therapeutic antibody discovery efforts. The partnership successfully produced potent binding antibodies against undisclosed cancer targets.
- FRONTEOcoreMOLCURE and FRONTEO signed a basic agreement on business alliance to promote drug discovery DX using AI. FRONTEO handles target discovery and selection while MOLCURE handles molecular design, enabling rapid candidate selection and efficacy verification.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Molcure competitors and assessment
Company assessmentDirect peers
- AbCellera Biologics: Public AI-driven antibody discovery platform that partners with pharma to screen and engineer therapeutic antibodies; competes head-to-head with Molcure in the antibody discovery service space using proprietary technology and partner-funded programs.
- Generate Biomedicines: Generative AI platform for designing novel protein therapeutics, including antibodies and peptides; directly comparable in using ML/AI to create biologics against challenging targets in partnership with pharma.
- BigHat Biosciences: AI/ML-driven antibody design platform combining wet-lab high-throughput experimentation with ML; mirrors Molcure's closed-loop approach to designing safer, more effective antibody therapeutics.
- Absci: Public company offering AI-powered biologic drug discovery, including generative AI for antibody design and a high-throughput wet lab; comparable as an integrated AI-plus-lab antibody discovery partner to pharma.
- Cradle Bio: Generative AI platform for protein engineering serving biotech and pharma partners; comparable to Molcure in using generative models plus experimental validation to design novel biologics for partner pipelines.
- Adagene: Clinical-stage AI-driven antibody platform focused on oncology biologics; comparable as a company using AI/computational biology to discover and optimize therapeutic antibodies for pharma-style collaborations.
Emerging players
- Profluent Bio: AI protein design company applying large language models to protein engineering; overlaps with Molcure's proprietary Antibody LLM approach, though Profluent is earlier-stage and broader in scope.
Broad incumbents
- Schrödinger: Public AI-driven molecular simulation and drug discovery platform with a broad small-molecule focus that increasingly extends into biologics; a broader incumbent with overlapping computational drug discovery capabilities.
- Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML; larger-scale platform incumbent operating across multiple therapeutic areas, including biologics-adjacent work.
- Insitro: AI-driven drug discovery company combining ML with high-throughput biology for pharma partners; broader incumbent with overlapping AI-plus-lab infrastructure approach, though focused more on small molecules and disease modeling.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Molcure social profiles
Digital presenceMolcure financial estimates
Financial estimateRevenue estimate
Valuation estimate
Molcure leadership team
Management profileNumber of profiles
Profiles8 records
Molcure funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Molcure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Molcure
What does Molcure do?
MOLCURE provides AI-driven antibody and peptide drug discovery services through a proprietary platform that integrates a biological Large Language Model, physics-based simulations, and high-quality experimental data generated in its in-house automated BioLab. The company engages pharmaceutical and biotechnology partners via multi-year collaborative research agreements covering end-to-end molecular design, AI-powered de novo discovery, lead optimization, and consulting, enabling discovery of high-affinity biotherapeutics against challenging targets.
Is Molcure a public or private company?
Molcure is a private company. It is classified as venture growth investor backed and is currently operating.
When was Molcure founded?
Molcure was founded in 2013. It employs 11 to 50 people.
Where is Molcure based?
Molcure is headquartered in Tokyo, Japan, in the Asia region.
How does Molcure make money?
Two revenue lines are on record. Collaborative Research Agreements are the primary driver. The others are AI Platform Licensing.
Who are Molcure's main competitors?
Direct peers on record are AbCellera Biologics, Generate Biomedicines, BigHat Biosciences, Absci, Cradle Bio and Adagene. Profluent Bio is listed as an emerging player. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Insitro.
Does Molcure have an API?
No public API is recorded for Molcure.
What industry is Molcure in?
Molcure's product category is AI-Driven Biologics Drug Discovery. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.